Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial
- Melior’s therapeutic candidate, tolimidone, is:
-
- Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications
-
- A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies